Takeda says zasocitinib showed superior efficacy in Phase 3 psoriasis study

Takeda said new Phase 3 LATITUDE Atlas data showed zasocitinib was statistically superior to deucravacitinib across primary and key secondary endpoints. The company also cited durable skin clearance and no new safety signals.